This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignees: Nippon Fine Chemical Co., Ltd., Shizuoka Prefectural University Corporation. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: Naofumi Fukata: Innovator in Lipid Technology
Introduction
Naofumi Fukata is a notable inventor based in Hyogo, Japan. He has made significant contributions to the field of lipid technology, particularly in the development of lipid particles for medicinal applications. His innovative work focuses on enhancing the delivery of therapeutic substances through lipid-based systems.
Latest Patents
Fukata holds a patent for a "Lipid derivative for nucleic acid introduction." The objective of this patent is to provide a lipid particle that is not positively charged at a pH typical of body fluids, which allows for the efficient onset of the effects of medicinal substances encapsulated within the lipid particle. The invention is achieved through a specific phospholipid formula, which includes a lipid particle containing this phospholipid. This advancement is crucial for improving the efficacy of drug delivery systems.
Career Highlights
Throughout his career, Naofumi Fukata has worked with reputable organizations, including Nippon Fine Chemical Co., Ltd. and Shizuoka Prefectural University Corporation. His experience in these institutions has allowed him to refine his expertise in lipid technology and contribute to various research initiatives.
Collaborations
Fukata has collaborated with notable colleagues such as Tomohiro Asai and Noriyuki Maeda. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.
Conclusion
Naofumi Fukata's contributions to lipid technology and his innovative patent demonstrate his commitment to advancing medicinal delivery systems. His work continues to influence the field and pave the way for future developments in drug delivery technologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile